Fampyra (fampridine)
- Region
- 🇪🇺 EU
- Active substance
- fampridine
- Company
- Merz Therapeutics GmbH
- Status
- Authorised
- Therapeutic area
- Multiple Sclerosis
- EU approval
- Wed 20 Jul 2011
- Application
- EMEA/H/C/002097
- ATC
- N07XX07
- Official record
- www.ema.europa.eu
Indication
Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4-7).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fampridine Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Firdapse (previously Zenas) Authorised · SERB SA
- 🇪🇺 Amifampridine SERB Authorised · SERB SA
Follow Fampyra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.